GC–MS–Identified Phytochemicals from Dimocarpus longan Leaves as Promising HER2 Inhibitors for Breast Cancer: Molecular Docking, ADMET, and Toxicity Assessment

As-Sazzad Mahmud; Md. Fozla Rabby; Md. Foyzur Rahman; Anwara Begum

doi:10.53941/npa.2026.100002

Abstract

Breast cancer is still a leading cause of cancer-related deaths globally, and human epidermal growth factor receptor 2 (HER2) overexpression is known to be associated with aggressive tumor characteristics and drug resistance. Although the development of clinically used HER2 inhibitors has shown improved outcomes for patients, their efficacy is often hampered by factors such as low bioavailability, drug resistance, and toxicity. In this research, the leaves of Dimocarpus longan were investigated as a natural source of new lead compounds for the development of next-generation HER2 inhibitors. Phytochemicals isolated from methanolic extracts of the leaves were assessed using an integrated computational approach that included molecular docking, pharmacokinetic analysis, toxicity prediction, and structure-activity relationship analysis. Some phytocompounds showed positive binding affinity interactions with the HER2 kinase domain, displaying affinity interaction profiles similar to known HER2 kinase inhibitors, including essential hydrogen bonding and hydrophobic interactions in the active site. In silico pharmacokinetic analysis showed that many compounds had desirable drug-likeness properties, including good gastrointestinal absorption and conformance to essential medicinal chemistry guidelines. Moreover, toxicity profiling indicated lower probabilities of hepatic, neurological, and immunological toxicities for some candidates. Structure-activity relationship analysis emphasized the significance of harmonious polar functional groups and hydrophobic cores in potentiating HER2 kinase inhibition. In conclusion, the results suggest that D. longan-derived phytocompounds are promising candidates for the development of safer and more bioavailable HER2-targeting drugs. Further experimental verification and rational optimization are required to translate these candidates into potential therapeutic agents for HER2-positive breast cancer.

References

1.
Kim, J.; Harper, A.; McCormack, V.; et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat. Med. 2025, 31, 1154–1162.
2.
Liao, L. Inequality in breast cancer: Global statistics from 2022 to 2050. Breast 2025, 79, 103851.
3.
Wang, J.; Xu, B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct. Target. Ther. 2019, 4, 34.
4.
Giuliano, M.; Trivedi, M.V.; Schiff, R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: Molecular basis and clinical implications. Breast Care 2013, 8, 256–262.
5.
Sikdar, N.; Saha, G.; Dutta, A.; et al. Genetic alterations of periampullary and pancreatic ductal adenocarcinoma: An overview. Curr. Genomics 2018, 19, 444–463.
6.
Slamon, D.J.; Clark, G.M.; Wong, S.G.; et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177–182.
7.
Gezici, S.; Şekeroğlu, N. Current perspectives in the application of medicinal plants against cancer: Novel therapeutic agents. Anti-Cancer Agents Med. Chem. 2019, 19, 101–111.
8.
Ilaro, F.P. In silico anticancer assessment of the bioactive compounds of Aframomum melegueta on HER2 protein associated with breast cancer. Int. J. Women Tech. Educ. Employ. 2023, 4, 1–15.
9.
Govindappa, M. A review on role of plant extracts and their phytochemicals for the management of diabetes. J. Diabetes Metab. 2015, 6, 7.
10.
Bolaji, O.Q.; Adelusi, T.I.; Ojo, T.O.; et al. Leveraging computational approaches in identifying novel HER2+ breast cancer potential therapeutics: Integrating virtual screening and molecular dynamics simulation. Future J. Pharm. Sci. 2025, 11, 1.
11.
Bose, R.; Kavuri, S.M.; Searleman, A.C.; et al. Activating HER2 mutations in HER2 gene amplification-negative breast cancer. Cancer Discov. 2013, 3, 224–237.
12.
Bilancia, D.; Rosati, G.; Dinota, A.; et al. Lapatinib in breast cancer. Ann. Oncol. 2007, 18, vi26–vi30.
13.
Elekofehinti, O.O.; Ejelonu, O.C.; Kamdem, J.P.; et al. Discovery of potential visfatin activators using in silico docking and ADME predictions as therapy for type 2 diabetes. Beni-Suef Univ. J. Basic Appl. Sci. 2018, 7, 241–249.
14.
Ramasamy, S.; Jeyaram, K.; Narayanan, A.; et al. Repurposing fluvoxamine as an inhibitor for NUDT5 in breast cancer cells: An in silico and in vitro study. In Silico Pharmacol. 2024, 13, 5.
15.
Medina, P.J.; Goodin, S. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 2008, 30, 1426–1447.
16.
Elkamhawy, A.; Son, S.; Lee, H.Y.; et al. Design, synthesis, biological evaluation, and molecular dynamics studies of novel lapatinib derivatives. Pharmaceuticals 2022, 16, 43.
17.
Abramson, H.N. The lipogenesis pathway as a cancer target. J. Med. Chem. 2011, 54, 5615–5638.
18.
Aertgeerts, K.; Skene, R.; Yano, J.; et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J. Biol. Chem. 2011, 286, 18756–18765.
19.
Karbownik, A.; Sobańska, K.; Płotek, W.; et al. The influence of the coadministration of the P-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. Investig. New Drugs 2020, 38, 574–583.
20.
Aqil, F.; Munagala, R.; Jeyabalan, J.; et al. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 2013, 334, 133–141.
21.
Zhou, Y.; Gong, J.; Deng, X.; et al. A comprehensive exploration of adverse reactions to lapatinib: A disproportionate analysis based on the FAERS database. Expert Opin. Drug Saf. 2025, 24, 1521–1530.
22.
Elwaie, T.A.; Abbas, S.E.; Aly, E.I.; et al. HER2 kinase-targeted breast cancer therapy: Design, synthesis, and in vitro and in vivo evaluation of novel lapatinib congeners as selective and potent HER2 inhibitors with favorable metabolic stability. J. Med. Chem. 2020, 63, 15906–15945.
23.
Ghosh, S. Triterpenoids: Structural diversity, biosynthetic pathway, and bioactivity. Stud. Nat. Prod. Chem. 2020, 67, 411–461.
24.
White, N.J. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans. R. Soc. Trop. Med. Hyg. 1994, 88, 41–43.
25.
Tinkov, O.V.; Ognichenko, L.N.; Kuz’min, V.E.; et al. Computational assessment of environmental hazards of nitroaromatic compounds: Influence of the type and position of aromatic ring substituents on toxicity. Struct. Chem. 2016, 27, 191–198.
26.
Shipunova, V.O.; Kolesnikova, O.A.; Kotelnikova, P.A.; et al. Comparative evaluation of engineered polypeptide scaffolds in HER2-targeting magnetic nanocarrier delivery. ACS Omega 2021, 6, 16000–16008.
27.
Shi, H.; Zhang, W.; Zhi, Q.; et al. Lapatinib resistance in HER2+ cancers: Latest findings and new concepts on molecular mechanisms. Tumour Biol. 2016, 37, 15411–15431.
28.
Dai, X.; Zhang, X.; Chen, W.; et al. Dihydroartemisinin: A potential natural anticancer drug. Int. J. Biol. Sci. 2021, 17, 603.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us